Evidence mapPaperPMID 40827730Full record

ArticleEuropean heart journal2025

LIPA, a risk locus for coronary artery disease: decoding the variant-to-function relationship.

Fang Li, Elise Flynn, Philip Ha, Mazal N Zebak, Haoxiang Cheng, Chenyi Xue, Jianting Shi, Xun Wu, Ziyi Wang, Yujiao Meng and 13 more

Abstract read
In one paragraph

Article in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Enhancer Dynamics for Gene Regulation in the Cardiovascular System.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Fang LiCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.ORCID 0000-0001-9180-3615
Elise FlynnNew York Genome Center, New York, NY 10013, USA.
Philip HaCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Mazal N ZebakCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Haoxiang ChengDepartment of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Chenyi XueCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Jianting ShiCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Xun WuCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Ziyi WangCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Yujiao MengCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Jian CuiCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Yizhou ZhuDepartment of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Annie RozenblyumCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Jeana ChunCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Antonio Hernandez-OnoDepartment of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
Ali JavaheriCardiovascular Division, Washington University School of Medicine, St Louis, MO 63110, USA.
Babak RazaniDivision of Cardiology and Vascular Medicine Institute, Department of Medicine, Department of Veterans Affairs, University of Pittsburgh, Pittsburgh, PA 15213, USA.
Marit WesterterpDepartment of Pediatrics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-2230-1659
Robert C BauerCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.
Yousin SuhDepartment of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY 10032, USA.
Ke HaoDepartment of Genetic and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0002-1815-9197
Tuuli LappalainenNew York Genome Center, New York, NY 10013, USA.ORCID 0000-0002-7746-8109
Hanrui ZhangCardiometabolic Genomics Program, Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, 630 West 168th St, P&S 10-401, New York, NY 10032, USA.ORCID 0000-0001-8655-938X

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · COLUMBIA UNIV NEW YORK MORNINGSIDE · 1985 to 2025
$22.9M
Translational Biomarker Analytical Core (TBAC)P30DK063608 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2003 to 2025
$8.5M
Validation and characterization of the identified variants associated with human longevity in mouse modelsU19AG056278 · ALBERT EINSTEIN COLLEGE OF MEDICINE · 2025 to 2025
$2.6M
Mouse and Human Atherosclerotic TissueP01HL172741 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$2.5M
Integrative analysis of genetic variation and transcription factor networks to elucidate mechanisms of mental health disordersR01MH106842 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Harmen J Bussemaker, Tuuli Lappalainen · 2022 to 2024
$2.3M
Integrative genomic and functional genomic studies to connect variant to function for CAD GWAS lociR01HL168174 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$770k
Finding and pushing the limits of macrophage efferocytosis in atherosclerosisR35HL177389 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$687k
American Heart Association-American Stroke Association 20POST35130003 - FANG LIAmerican Heart Association-American Stroke Association 23CDA1052177NCI NIH HHS P30 CA013696NCRR NIH HHS S10 RR027050NHGRI NIH HHS F31 HG010580NHLBI NIH HHS P01 HL172741NHLBI NIH HHS R00 HL130574NHLBI NIH HHS R01 HL151611NHLBI NIH HHS R01 HL168174NHLBI NIH HHS R35 HL177389NIA NIH HHS U19 AG056278NIDDK NIH HHS P30 DK063608NIH HHS P30CA013696NIH HHS P30DK063608NIH HHS S10 OD019973NIH HHS S10OD019973NIH HHS S10 OD020056NIH HHS S10OD020056NIH HHS S10RR027050NIMH NIH HHS R01 MH106842
6 · The paper itself

Abstract

BACKGROUND AND

aimsTranslating human genomic discoveries into mechanistic insights requires linking genetic variations to candidate genes and their causal functional phenotypes. Genome-wide association studies have consistently identified LIPA (lipase A, lysosomal acid type) as a risk locus for coronary artery disease, with previous analyses prioritising LIPA as a likely causal gene. However, functional studies elucidating causal variants, regulatory mechanisms, target cell types, and their causal impact on atherosclerosis have been lacking. This study aims to address this gap by establishing the variant-to-function relationship at the LIPA locus.

methodsPost-genome-wide association study pipelines and molecular biology techniques, including expression quantitative trait loci analysis, Tri-HiC, luciferase assay, CRISPRi, allele-specific binding, motif analysis, and electrophoretic mobility shift assay, were used to link functional variants to target genes and define the direction of their regulatory effects in causal cell types. To determine how increased myeloid LIPA impacts atherosclerosis, myeloid-specific Lipa overexpression mice on an Ldlr-/- background were generated.

resultsCoronary artery disease-risk alleles in the LIPA locus increase LIPA expression and enzyme activity specifically in monocytes/macrophages by enhancing PU.1 binding to an intronic enhancer region that interacts with the LIPA promoter. Myeloid-specific Lipa overexpression in Ldlr-/- mice fed a western diet resulted in larger atherosclerotic lesions, accompanied by altered macrophage function, characterized by increased accumulation of lesional macrophages derived from circulating monocytes, reduced neutral lipid content, and up-regulation of integrin and extracellular matrix pathway genes.

conclusionsThe work establishes a direct causal link between LIPA-risk alleles and increased monocyte/macrophage LIPA that exacerbates atherosclerosis, bridging human functional genomic evidence to the mechanistic understanding of coronary artery disease.

Indexed as

Coronary Artery DiseaseAnimalsGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansMicePolymorphism, Single NucleotideQuantitative Trait LociSterol EsteraseLIPA protein, humanSterol EsteraseAtherosclerosisFunctional genomicsGWASLysosomal acid lipaseMacrophage

Identifiers

PMID40827730
PMCPMC12461605

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.